Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Completed 95Active not recruiting 62Recruiting 54Terminated 51Unknown 20Withdrawn 11Not yet recruiting 3Suspended 2No longer available 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Carcinoma, Non-Small-Cell Lung 10Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Breast Neoplasms 5Head and Neck Neoplasms 4Carcinoma, Renal Cell 4Turcot syndrome 3Melanoma 3Lung Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hodgkin Disease 2Glioblastoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Biliary Tract Neoplasms 2Advanced Endometrial Cancer 2Tongue Neoplasms 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Thyroid Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous NSCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1

Interventions

Nivolumab 6pembrolizumab 3Specimen Handling 3Ipilimumab 3relatlimab 2cemiplimab 2Melphalan 2Magnetic Resonance Spectroscopy 2Interleukin-2 2vedolizumab 1trametinib 1toripalimab 1sulforaphane 1gadopiclenol 1famitinib 1anlotinib 1X-Rays 1Watchful Waiting 1Ultraviolet Therapy 1Toll-Like Receptor 1 1Therapeutics 1Temozolomide 1Technetium 1Standard of Care 1Sentinel Lymph Node Biopsy 1SHR-1701 1Rehabilitation 1Phototherapy 1Photopheresis 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Melanoma × pembrolizumab × Clear all
NCT07565285 2026-05-04

INFLECTION-003

Primmune Therapeutics, Inc.

Phase 2 Not yet recruiting
48 enrolled
Dermatologic

Melanoma

NCT07475572 2026-03-16

A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

Alvotech Swiss AG

Phase 1 Not yet recruiting
120 enrolled
Dermatologic

Melanoma

NCT06212388 2024-01-25

Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma

Xijing Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡